Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/5/2020
SIETES contiene 93008 citas

 
 
 1 a 20 de 69 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
2. Cita con resumen
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010;33:713-26. [Ref.ID 89267]
3. Cita con resumen
Ibáñez L, Vidal X, Laporte JR. Proton pump inhibitors and risk of upper gastrointestinal bleeding in NSAID users. Am J Gastroenterol 2008;103:2658-1659. [Ref.ID 84102]
4.
Anónimo. Hypoglycémies d'origine médicamenteuse. Prescrire 2008;28:665-70. [Ref.ID 83947]
5. Cita con resumen
Anónimo. Interacciones del acenocumarol con importancia clínica. Boletín Terapéutico Andaluz 2004;20:1-4. [Ref.ID 70099]
7.
Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25:233-50. [Ref.ID 61879]
8.
Anónimo. Review of ADRs. Anti-inflammatory analgesics. Hepatic reactions, Finland. WHO Pharmaceuticals Newsletter 2001;1:12-3. [Ref.ID 56635]
9.Tiene citas relacionadas Cita con resumen
Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med 1998;105:13S-9S. [Ref.ID 50997]
10. Cita con resumen
Zanfi D. Deficit di glucosio-6-fosfato deidrogenasi: quali farmaci evitare?. Informazioni sui Farmaci 1999;23:139-40. [Ref.ID 48251]
11.
Vervloet D, Durham S. Adverse reactions to drugs. BMJ 1998;316:1511-4. [Ref.ID 39789]
12. Cita con resumen
Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38. [Ref.ID 38706]
13. Cita con resumen
van der Klauw MM. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands. Pharmacoepidemiol Drug Saf 1997;6:8. [Ref.ID 34036]
14. Cita con resumen
Anónimo. Drug-induced agranulocytosis. Drug Ther Bull 1997;35:49-52. [Ref.ID 33485]
16. Cita con resumen
Stich W, Thierfelder S. Die therapie der agranulozytose. Ther Ggw 1967;106:1083-1086,1088-1090,1092-1093. [Ref.ID 30984]
17. Cita con resumen
Manoukian AV, Carson JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 1996;15:64-71. [Ref.ID 28525]
18.Tiene citas relacionadas Cita con resumen
Moxley TE, Royer G L, Hearron MS, Donovan JF, Levi L. Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. J Am Geriatr Soc 1975;23:343-9. [Ref.ID 24283]
19.
Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441-9. [Ref.ID 20787]
20. Cita con resumen
Anónimo. Dug-induced neutropenia and agranulocytosis. Curr Probl Pharmacov 1993;19:10-1. [Ref.ID 20594]
Seleccionar todas
 
 1 a 20 de 69 siguiente >>